UNSPSC 51361927: Probarbital

This classification denotes a barbiturate with the molecular formula C9H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R87TF75S6O, chemically known as 5-ethyl-5-propan-2-yl-1,3-diazinane-2,4,6-trione but generally known as probarbital, which bears US NIH Compound Identifier 6455. European Medicines Agency schedules Probarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10052MIG. The term PROBARBITAL is an International Non-Proprietary Name.

As of Q4 2014, PROBARBITAL remains the US FDA Preferred Term for this commodity. SMILES: CCC1(C(=O)NC(=O)NC1=O)C(C)C.

UNSPSC 51361927 Probarbital is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceuticals and drug-related products to public health agencies, though the recent solicitations show limited direct purchasing of the code's nominal product in favor of broader pharmaceutical procurement and harm-reduction supplies. State and local governments soliciting under this code include county health departments, state human services commissions, and multi-state cooperative purchasing alliances serving healthcare facilities and public health initiatives. Seminole County, Florida's IFB for naloxone and drug deactivation systems exemplifies the health-support focus, while the Texas Health and Human Services Commission's exploratory RFI on direct-to-manufacturer prescription programs and the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceutical RFP represent the range of issuing bodies and procurement strategies in play—from informal information gathering to formal competitive bidding for pharmaceutical supply contracts.

Geographic activity centers on Florida, Texas, and Minnesota, with multi-state cooperative purchasing mechanisms extending reach across additional jurisdictions including Oregon. Recent opportunities include Seminole County's IFB (due July 26, 2023) seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries; the Texas HHS Commission's RFI (response deadline April 3, 2026) on direct-to-manufacturer prescription fulfillment; and the Minnesota Department of Administration's RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and performance penalties of $200 to $1,500 per violation. The Seminole County contract includes a two-year initial term with one-year renewal option and potential FEMA funding, while MMCAP's procurement carries a two-year term with optional extensions and mandates cGMP certification and Drug Supply Chain Security Act compliance.